TW464496B - Pharmaceutical composition and kit for the treatment of bone disorders - Google Patents
Pharmaceutical composition and kit for the treatment of bone disorders Download PDFInfo
- Publication number
- TW464496B TW464496B TW085115770A TW85115770A TW464496B TW 464496 B TW464496 B TW 464496B TW 085115770 A TW085115770 A TW 085115770A TW 85115770 A TW85115770 A TW 85115770A TW 464496 B TW464496 B TW 464496B
- Authority
- TW
- Taiwan
- Prior art keywords
- compound
- phenyl
- pharmaceutical composition
- cis
- refers
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH] (Somatotropin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone (parathormone); Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/975—Kit
Description
464496
'申請專利範圍 6 ’ 7 ’ 8 -四氫伸棻一 2 -醇;順—1 一〔 6 >吡咯啶 基乙氧基〜3 ――吡啶基〕一 2 —苯基一 6 —羥基一 1 , 2 ’ 3 ’ 4 —四氫伸棻;1一(4>一吡咯啶基乙氧基苯 基)—(4〃 一氟苯基)一 6 一羥基一丄,2,3, 4〜四氫異暗啉;順一 6 一(4 一羥基苯基)一 5 -〔4 一(2 -六氫吡啶一 1基一乙氧基)—苯基〕—5,6 , 7 ’ 8-四氫伸某一 2 —醇;或1 一(4^ —吡咯啶基乙 氧基苯基)一 2 —苯基一 6 -羥基—1 ,2,3,4 一四 氫異瞎啉。 8..如申請專利範圍第7項之醫藥組成物,其中第二 化合物係指P G E 2。 9 ·如申請專利範圍第7項之醫藥組成物,其中第二 化合物係指3 S -(3 -羥基一 4 —苯基一 丁基)一 2R —〔6— (1氫一四嗤—5基)—己基〕一環戊酮。. 1 〇 · —種治療骨病症(包括骨質疏鬆症)之醫藥組 ,包括: a ·具有某種劑量之第一化合物,其係爲一種動情激 素促效劑/對抗劑;及 b ·具有某種劑量之第二化合物,其係爲一種前列腺 素或前列腺素促效劑/對抗劑; 其中,僅以第一化合物之劑量或第二化合物之劑量單 獨施藥時,其可達成的增加骨骼形成及降低骨骼耗損之療 效不及以兩者同時給藥時的療效;而兩者組合使用後之合 併功效遠大於任何使用由第一化合物、第二化合物及藥學 本紙張尺度逋用中國國家梂準(CNS〉A4规格(210X297公釐) (請先閱讀背面之注意事項再填寫本頁) 訂 經濟部智慧財產局員工消費合作社印製 -3 - 464496 A8 B8 C8 D8 々、申請專利範圍 上可接受的稀釋劑或載體之療效的總合,且 (請先閲讀背面之注意事項再填寫本頁) 其中動情激素促效劑/對抗劑是多羅西吩(droloxif ene)、羅拉西吩(rai〇xifene)、多嗎西吩(tamoxifene )、4 —經基—多嗎西吩(4 — hydroxy-tamoxifene)、 順一 6 — ( 4 —氟一苯基)—5 -〔 4 一( 2 —六氟吡啶 一 1基一乙氧基)一苯基〕—5 ,6 ,7,8 —四氫伸棻 一 2 -醇;(一)—順一 6 - 苯基一 5 -〔4— (2 — B比 咯*卩定一 1基一乙氧基)—苯基〕一 5 ,6 ,7 ,8 -四氫 伸棻一 2 -醇;順—6 —苯基一 5 -〔4 一(2 -吡咯啶 —1基一乙氧基)一苯基〕一 5 ,6 ,7 ,8 —四氫伸棻 一 2 -醇;順一 1 一〔 6 >吡咯啶基乙氧基一 3,一吡啶 基〕一 2 —苯基一 6 -羥基—1 ,2,3 ,4 一四氫伸棻 ;1— (4 一妣略σ定基乙氧基苯基)—2 —(4〃 —氟 苯基)—6 —羥基—1 ,2,3 ,4 一四氫異喹啉;順— 6 -(4 一羥基苯基)—5 -〔4 — (2 -六氫吡啶—1 基—乙氧基)—苯基〕—5 ,6 ,7,8 —四氫伸棻—2 —醇;及1一(4/一吡咯啶基乙氧基苯基)一2—苯基 —6 -經基一 1 ,2,3,4 一四氫異暗啉。 經濟部智慧財產局員工消費合作社印製 1 1 · 一種用以治療低骨骼質量病症之套組,其中包 括: a .第一單劑,內含一有效劑量之動情激素促效劑/ 對抗劑及藥學上可接受的載體; b ·第二單劑,內含一有效劑量之前列腺素或一前列 腺素促效劑/對抗劑及藥學上可接受的載體;及 本紙張尺度適用中國國家梂準(CNS ) A4規格(210 X 297公釐) 464496 A8 B8 C8 D8 六、申請專利範圍 C ·容器,用以裝載前述之第一單劑及第二單劑。 1 2 · —種治療骨病症(包括骨質疏鬆症)之醫藥組 成物,包括: (請先閱讀背面之注意事項再填寫本頁) a ·有效劑量之第一化合物,係指多羅西吩(dr〇i〇 一 xifene)、羅拉西吩(raloxifene)、多嗎西吩(tamoxif-ene)或哎晚西(idoxifene );及 b .有效劑量之第二化合物,係指氟化鈉或N —〔 1 (R) —〔1 ,2 —二氫一 1 一甲磺醯基螺〔3氫—口引跺 —3,4 — 一六氫吡啶〕一 1 /基)羰基〕一 2 -(苯基 乙氧基)乙基〕一 2 —胺基一 2 —甲基丙醯胺:MK — 6 7 7。 13·如申請專利範圍第12項之一種醫藥組成物, 並加上藥劑載體。 1 4 . 一種治療骨病症(包括骨質疏鬆症)之醫藥組 成物,包括: 經濟部智慧財產局員工消費合作社印製 a .有效劑量之第一化合物,係指多羅西吩(d:ro 1〇-xifene)、羅拉西吩(raloxifene)、多嗎西吩(tamoxif -ene)或哎晚西(idoxifene );及 b .有效劑量之第二化合物,係指氟化鈉或N -〔 1 (R) —〔1 ,2 —二氫一 1 一甲磺醯基螺〔3氫—σ引晚 —3,4 一六氫社^定〕—1 基)鑛基〕一 2 -(苯基 乙氧基)乙基〕一 2 —胺基一 2 —甲基丙醯胺:MK — 6 7 7; 其中,僅以第一化合物之劑量或第二化合物之劑量單 本紙张尺度逋用中國國家標準(CNS ) A4規格(210 X 297公釐) 464496 A8 B8 C8 D8 々、申請專利範圍 (請先閱讀背面之注意事項再填寫本頁) 獨施藥時,其可達成的增加骨骼形成及降低骨骼耗損之療 效不及以兩者同時給藥時的療效;而兩者組合使用後之合 併功效遠大於任何使用由第一化合物、第二化合物及藥學 上可接受的稀釋劑或載體之療效的總合。 1 5 . —種用以治療低骨骼質量病症之套組,其中包 括: a .第一單劑,內含有療效劑量之多羅西吩(drolo-xifene)、羅拉西吩(raloxifene)、多嗎西吩(tamoxif-ene)或哎薛西(idoxifene)及藥學上可接受的載體。 b .第二單劑,內含一有療效劑量之氟化鈉或N—〔 1 (R) —〔1 ,2 -二氫—1—甲磺醯基螺〔3氫一口引 口朵—3 ,4 一六氫U比淀〕一 1 基)鑛基〕一 2 -(苯 基乙氧基)乙基〕一 2 —胺基一2 —甲基丙醯胺:MK — 6 7 7及藥學上可接受的載體;及 c .容器,用以裝載前述第一劑及第二劑。 1 6 . —種治療骨病症(包括骨質疏鬆症)之醫藥組 成物,包括: 經濟部智慧財產局員工消費合作社印製 a · —有效劑量之第一化合物,係指順一 6 -( 4 — 氟一苯基)一 5 -〔4 一(2 —六氟U比u定一 1基—乙氧基 )一苯基〕—5,6,7,8 -四氫伸棻一 2 -醇;(一 )—順一 6 —苯基一 5 —〔4 一(2 -吡咯啶—1基—乙 氧基)一苯基〕一 5 ,6 ,7,8 -四氫伸某一 2 -醇; 順—6 -苯基—5 —〔4 — (2 — B比咯·ϋ定一 1基一乙氧基 )—苯基〕一 5,6,7,8 -四氫伸棻一 2 —醇;順一 本紙張尺度適用中國國家輮準(CNS ) Α4規格(210X297公釐) 464496 A8 B8 C8 __ D8 六、申請專利範圍 1 —〔 δ >吡咯啶基乙氧基一 3 > -吡啶基〕一 2 —苯基 —6 —羥基—1 ,2,3,4 一四氫伸某;1一(4 -一 社略11 定基乙氧基苯基)—2 -(4" 一氟苯基)—6 —羥 基一 1, 苯基)一 3 ,4 —四氫異喹啉;順—6 —(4 —羥基 〔4 一(2 —六氫妣d定一 1基—乙氧基)一 苯基 6 7,8 —四氫伸棻—2 —醇;及1 一 4 耻咯· a定基乙氧基苯基)一 2 —苯基一 6 —經基一 1 2 經濟部智慧財產局員工消费合作社印製 3,4一四氫異喹啉; b · —有效劑量之第二化合物,係指氟化鈉、副甲狀 Μ '生長荷爾蒙或生長荷爾蒙促泌素。 1 7 ·如申請專利範圍第1 6項之醫藥組成物,並加 上藥劑載體。 1 8 ·如申請專利範圍第1 7項之醫藥組成物,其中 第二化合物係指氟化鈉。 1 9 ·如申請專利範圍第1 7項之醫藥組成物,其中 第二化合物係指副甲狀腺素。 2 0 ·如申請專利範圍第1 7項之醫藥組成物,其中 第一化合物係指生長荷爾冡。 2 1 ·如申請專利範圍第1 7項之醫藥組成物,其中 第二化合物係指生長荷爾蒙促泌素。 2 2 . —種治療骨病症(包括骨質疏鬆症)之醫藥組 成物,包括: a ·某種劑量之第一化合物,係指順一 6 -( 4 一氟 —苯基)一 5 —〔4 — (2 —六氟吡啶一 1基一乙氧基) (請先閲讀背面之注意事項再填寫本頁) 本紙張尺度適用中國國家梯準(CNS ) A4規格(21〇Χ:297公釐) 464496 A8 B8 C8 D8 、申請專利範圍 經濟部智慧財產局員工消費合作社印製 — 苯 基 〕一 5 ϊ 6 7 ί 8 一 一 順 — 6 - 苯 基 — 5 一 C 4 一 基 ) — 苯基 ] 一 5 6 7 一 6 一 苯基 一 5 一 ( 4 一 ( 2 一 苯 基 〕一 5 > 6 7 9 8 一 一 C 6 /吡 咯 u定 基 乙 氧 基 一 3 6 — 羥 基一 1 > 2 > 3 9 4 一 咯 11定 基 乙氧 基 苯 基 ) 一 2 一 ( — 1 2, 3 y 4 — 四 氫 異 瞎 基 ) — 5 - 〔 4 一 ( 2 一 -JL- 氫 基 ] 一 5, 6 ϊ 7 , 8 一 四 氫 - — 吡 咯啶 基 乙 氧 基 苯 基 ) 一 2 3 ,4 一 四 氫 異 喹 啉 9 b •某 種 劑 里 之 第 二 化 合 生 長 荷爾 蒙 或 生 長 荷 爾 蒙 促 其 中, 僅 以 第 —» 化 合 物 之 獨 施 藥 時, 其 可 達 成 的 增 加 骨 效 不 及 以兩 者 同 時 給 藥 時 的 療 併 功 效 遠大 於 任 何 使 用 由 第 — 上 可 接 受的 稀 釋 劑 或 載 體 之 療 2 3 · 一 種 治 療 低 骨 骼 質 a .第 一 單 劑 > 內 含 有 效 一 6 一 (4 — 氟 一 苯 基 ) — 5 1 基 一 乙氧 基 ) 一 苯 基 ] — 5 本紙張尺度適用中國國家梂準(CNS ) A4说格(210X297公釐) 四氬伸某一 2 —醇;(―) (2 — CI比咯d定一 1基—乙氧 8 —四氫伸棻一 2 -醇;順 一吡咯啶一 1基一乙氧基) 四氫伸棻一 2 —醇;順—1 /一吡啶基〕一 2 -苯基一 四氫伸某;1 一( 4 > 一吡 4"一氟苯基)一6-羥基 啉;順一 6 — ( 4 -羥基苯 吡啶一 1基一乙氧基)一苯 伸棻一 2 -醇;或1 一( 4 2 -苯基一 6 -羥基—1 , 物,係指氟化鈉、副甲狀腺 泌素; 劑量或第二化合物之劑量單 骼形成及降低骨骼耗損之療 效;而兩者組合使用後之合 化合物、第二化合物及藥學 效的總合。 量病症之套組,其中包括: 劑量之第一化合物,泛指順 一〔4 - ( 2 -六氟吡啶一 ,6,7,8 —四氫伸棻一 (請先閲讀背面之注意事項再填寫本頁) 一 8 - 464496 經濟部智慧財產局員工消费合作社印製 A8 B8 C8 D8 六、申請專利範圍 2〜醇;(―)一順一 6 -苯基一 5—〔4 一(2-吡咯 11定〜1基一乙氧基)一苯基〕一 5 ,6 ,7 ,8 —四氫伸 条〜2 —醇,順—6 -苯基一 5 -〔4 — (2 -社略陡— 1基一乙氧基)一苯基〕一5 ,6 ,7 ,8 —四氫伸某一 2 —醇;順一1 一〔 6 /吡咯啶基乙氧基一 3 / -吡啶基 〕—2 —苯基一 6 -羥基一 1 ,2 ,3 ,4 一四氫伸棻; 1— (4 >一吡咯啶基乙氧基苯基)一 2— (4〃 一氟苯 基)一 6 -羥基一 1 ,2,3,4 一四氫異喹啉;順—6 〜(4 —羥基苯基)一 5 —〔4 一(2 —六氫吡啶一 1基 〜乙氧基)一苯基〕—5,6 ,7,8 —四氫伸棻—2 — 醇;或1-(4>一吡咯啶基乙氧基苯基)一2-苯基一 6 —羥基一 1 ,2,3,4 一四氫異瞎啉及藥學上可接受 的載體; b ·第二單劑,內含有一有效劑量之第二化合物,係 指氟化鈉、副甲狀腺、生長荷爾蒙或生長荷爾蒙促泌素及 藥學上可接受的載體;及 c ·容器,用以裝載前述第一劑及第二劑。 2 4 ·如申請專利範圍第1 2項之醫藥組成物,其中 第一組成物係指多羅西吩(droloxifene)。 2 5 ·如申請專利範圍第1 4項之一種醫藥組成物, 其中第一組成物係指多羅西吩(droloxifene)。 2 6 ·如申請專利範圍第1 5項之套組,其中第一組 成物係指多羅西盼(droloxifene)。 2 7 · —種治療骨病症(包括骨質疏鬆症)之醫藥組 本紙張尺度適用中國國家梂準(CNS ) A4規格(21〇X297公釐) , 訂 (請先閲讀背面之注意事項再填寫本頁) 464496 A8 B8 C8 D8 六、申請專利範圍 成物,包括: (請先閱讀背面之注意事項再填寫本頁) a . —有效劑量之第一化合物,係指羅拉西吩( raloxifene)、多嗎西吩(t a moxifene)或哎晚西(丨(1〇义1尤-e n e );及 b . —有效療效量之第二化合物,係指副甲狀腺素、 生長荷爾蒙或生長荷爾蒙促泌素, 但當該第一化合物爲羅拉西吩時,該第二化合物不是 副甲狀腺素。 2 8 .如申請專利範圍第2 7項之醫藥組成物,並加 上藥劑載體。 2 9 ·如申請專利範圍第2 8項之醫藥組成物,其中 第一組成物係指羅拉西吩(raloxifene)。 3 0 ·如申請專利範圍第2 8項之醫藥組成物,其中 第二化合物係指副甲狀腺素。 3 1 ·如申請專利範圍第2 8項之醫藥組成物,其中 第二化合物係指生長荷爾蒙。 3 2 .如申請專利範圍第2 8項之醫藥組成物,其中 第二化合物係指生長荷爾蒙促泌素。 經濟部智慧財產局員工消費合作社印製 3 3 · —種治療骨病症(包括骨質疏鬆症)之醫藥組 成物,包括: a . —有效劑量之第一化合物,係指羅拉西吩( raloxifene)、多嗎西吩(tamoxifene)或哎晚西(idoxif -e n e );及 b · —有效劑量之第二化合物,係指副甲狀腺素、生 本紙张尺度適用中國國家梂準(CNS ) A4规格(210X297公釐)~ 464496 A8 B8 C8 D8 六、申請專利範圍 長荷爾蒙或生長荷爾蒙促泌素; (請先閲讀背面之注意事項再填寫本頁) 其中,僅以第一化合物之劑量或第二化合物之劑量單 獨施藥時,其可達成的·增加骨骼形成及降低骨骼耗損之療 效不及以兩者同時給藥時的療效;而兩者組合使用後之合 併功效遠大於任何使用由第一化合物、第二化合物及藥學 上可接受的稀釋劑或載體之療效的總合, 但當該第一化合物爲羅拉西吩時,該第二化合物不是 副甲狀腺素。 3 4 . —種治療低骨骼質量病症之套組,其中包括: a ·第一單劑,內含有療效劑量之下列化合物及藥學 上可接受的載體、羅拉西吩(raloxifene)、多嗎西吩( tamoxi fene )或哎 口朵西(idoxifene)·, b ·第二單劑,內含有效劑量之下列化合物及藥學上 可接受的載體:副甲狀皞素、生長荷爾蒙或生長荷爾 蒙促泌素;及 c .容器,用以裝載前述第一劑及第二劑, 但當該第一化合物爲羅拉西吩時,該第二化合物不是 經濟部智慧財產局員工消費合作社印製 素 腺 狀I 甲 副 本紙張尺度適用中國國家梂準(CNS ) A4規格(210X297公釐) 11
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1241296P | 1996-02-28 | 1996-02-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
TW464496B true TW464496B (en) | 2001-11-21 |
Family
ID=21754846
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW085115770A TW464496B (en) | 1996-02-28 | 1996-12-20 | Pharmaceutical composition and kit for the treatment of bone disorders |
Country Status (45)
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5552412A (en) * | 1995-01-09 | 1996-09-03 | Pfizer Inc | 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis |
HN1996000101A (es) * | 1996-02-28 | 1997-06-26 | Inc Pfizer | Terapia combinada para la osteoporosis |
AR008155A1 (es) * | 1996-09-06 | 1999-12-09 | Smithkline Beecham Corp | Uso de un compuesto de formula i para preparar un medicamento util para tratar y prevenir la enfermedad cardiovascular post menopausica en mujeres. |
GB2324726A (en) * | 1997-05-01 | 1998-11-04 | Merck & Co Inc | Combination Therapy for the Treatment of Osteoporosis |
SE9702401D0 (sv) * | 1997-06-19 | 1997-06-19 | Astra Ab | Pharmaceutical use |
WO1998058911A2 (en) * | 1997-06-23 | 1998-12-30 | Pfizer Inc. | Prostaglandin agonists |
ID24759A (id) * | 1997-09-09 | 2000-08-03 | Procter & Gamble | Metoda untuk meningkatkan volume tulang |
UA67754C2 (uk) * | 1997-10-10 | 2004-07-15 | Пфайзер, Інк. | Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти) |
EP0950417A3 (en) * | 1998-02-23 | 2000-02-23 | Pfizer Products Inc. | Treatment of skeletal disorders |
ES2235475T3 (es) * | 1998-06-03 | 2005-07-01 | Pfizer Products Inc. | 2-aminopiridinas que contienen sustituyentes de anillos condensados como inhibidores de oxido nitrico sintasa. |
ATE265853T1 (de) * | 1998-06-16 | 2004-05-15 | Pfizer Prod Inc | Kombinationstherapeutika, enthaltend einen selektiven östrogenrezeptormodulator und prostaglandin e2 |
JP2002518328A (ja) * | 1998-06-16 | 2002-06-25 | ファイザー・プロダクツ・インク | 筋骨格虚弱の治療用の(選択的)エストロゲン受容体モジュレーター(serm)および成長ホルモン分泌促進薬(ghs)の治療的組合せ |
AR018869A1 (es) * | 1998-06-16 | 2001-12-12 | Pfizer Prod Inc | Composicion farmaceutica, su uso para la preparacion de medicamentos y estuche que la contiene |
PA8471201A1 (es) * | 1998-06-16 | 2000-09-29 | Pfizer Prod Inc | Combinaciones terapeuticas que comprenden un modulador del receptor de estrogenos selectivo y hormona paratiroidea |
EP1004306A3 (en) * | 1998-08-06 | 2000-06-07 | Pfizer Products Inc. | Estrogen agonists/antagonists |
US6414006B1 (en) | 1998-10-15 | 2002-07-02 | Merck Frosst Canada & Co. | Methods for inhibiting bone resorption |
AU5995299A (en) | 1998-11-03 | 2000-05-22 | Pfizer Products Inc. | Novel macrolide antibiotics |
CA2365326A1 (en) * | 1999-03-05 | 2000-09-08 | The Procter & Gamble Company | Methods of increasing bone volume using non-naturally-occurring fp selective agonists and antiresorptive compounds |
GB9913649D0 (en) * | 1999-06-11 | 1999-08-11 | Karobio Ab | Estrogen receptor |
EP1113007A1 (en) * | 1999-12-24 | 2001-07-04 | Pfizer Inc. | Tetrahydroisoquinoline compounds as estrogen agonists/antagonists |
CO5251465A1 (es) | 2000-01-26 | 2003-02-28 | Pfizer Prod Inc | Composiciones y procedimientos para tratar la osteoporosis y reducir el colesterol |
NZ516582A (en) * | 2000-06-01 | 2004-08-27 | Watson Pharmaceuticals Inc | Transdermal delivery of lasofoxifene |
EP1192945A3 (en) * | 2000-09-21 | 2004-03-03 | Pfizer Products Inc. | Use of an estrogen agonist/antagonist for treating osteoarthritis |
TWI303990B (en) * | 2000-10-17 | 2008-12-11 | Pfizer Prod Inc | New use of estrogen agonists/antagonists for improving vascular health |
ES2233570T3 (es) * | 2000-11-30 | 2005-06-16 | Pfizer Products Inc. | Composicion que contiene agonistas/antagosnistas de estrogenos y testosterona para tratar un descenso en el nivel de la hormona testosterona. |
WO2003011282A1 (en) * | 2001-07-31 | 2003-02-13 | Pfizer Products Inc. | Pharmaceutical compositions, kits and methods comprising combinations of estrogen agonists/antagonists, estrogens and progestins |
TWI316511B (en) | 2002-11-26 | 2009-11-01 | Smithkline Beecham Corp | Calcilytic compounds |
US8853423B2 (en) | 2010-06-17 | 2014-10-07 | Seragon Pharmaceuticals, Inc. | Indane estrogen receptor modulators and uses thereof |
WO2013049507A1 (en) | 2011-09-30 | 2013-04-04 | Perio Sciences, Llc | Antioxidant compositions for treatment of inflammation or oxidative damage |
CN103142644B (zh) * | 2013-03-21 | 2014-07-23 | 青岛正大海尔制药有限公司 | 骨化三醇和氟化钠的混悬颗粒及其制备方法 |
PL3525774T3 (pl) | 2016-10-11 | 2022-04-25 | Duke University | Leczenie lazofoksyfenem raka piersi er+ |
WO2019199891A1 (en) | 2018-04-10 | 2019-10-17 | Duke University | Lasofoxifene treatment of breast cancer |
CN112384634B (zh) * | 2018-04-24 | 2024-04-16 | 深圳华大生命科学研究院 | 骨质疏松生物标志物及其用途 |
CN110412289B (zh) * | 2019-07-25 | 2022-08-02 | 北京美迪阿姆科技发展有限公司 | 抑制性t细胞及筛选方法和抑制自身免疫反应中的应用 |
Family Cites Families (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3274213A (en) | 1961-09-05 | 1966-09-20 | Upjohn Co | Alkoxy-substituted 2-phenyl-1-(tertiary-aminoalkoxy)phenyl-3, 4-dihydronaphthalenes |
US3234090A (en) | 1962-09-10 | 1966-02-08 | Ciba Geigy Corp | Pharmaceutical compositions comprising saturated basic ethers |
BE637389A (zh) | 1962-09-13 | |||
US3522319A (en) | 1964-01-23 | 1970-07-28 | Ciba Geigy Corp | Phenol substituted tetrahydronaphthalenes useful as estrogenics |
US3822287A (en) | 1969-04-17 | 1974-07-02 | Rexall Drug Chemical | Process for preparation of substituted 3,4-(diphenyl)chromans |
US3927197A (en) | 1974-04-19 | 1975-12-16 | Pfizer | Tertiary alcohol stabilized E-series prostaglandins |
US3932389A (en) | 1974-12-11 | 1976-01-13 | Pfizer Inc. | 2-Descarboxy-2-(tetrazol-5-yl)-11-desoxy-15-substituted-.omega.-pentanorprostaglandins |
US3982016A (en) | 1975-08-06 | 1976-09-21 | Pfizer Inc. | Bone deposition by 16-aryl-13,14-dihydro-PGE2 p-biphenyl esters |
US4000309A (en) | 1975-08-06 | 1976-12-28 | Pfizer Inc. | Bone deposition by 16-aryl-13,14-dihydro-PGE2 p-biphenyl esters |
US4018892A (en) | 1975-08-06 | 1977-04-19 | Pfizer Inc. | Bone deposition by 16-aryl-13,14-dihydro-PGE2 p-biphenyl esters |
US4133814A (en) | 1975-10-28 | 1979-01-09 | Eli Lilly And Company | 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents |
US4132847A (en) | 1977-07-22 | 1979-01-02 | Pfizer Inc. | 4-Pyrone prostaglandin antagonists |
EP0002097B1 (en) | 1977-08-22 | 1981-08-05 | Imperial Chemical Industries Plc | Triphenylalkene derivatives, process for their preparation and pharmaceutical compositions containing them |
US4097601A (en) | 1977-08-26 | 1978-06-27 | Pfizer Inc. | Bone deposition by 2-descarboxy-2-(tetrazol-5-yl)-11-dexosy-16-aryl prostaglandins |
US4171331A (en) | 1978-06-05 | 1979-10-16 | Miles Laboratories, Inc. | 1 And 2-substituted analogues of certain prostaglandins |
US4219483A (en) | 1978-09-11 | 1980-08-26 | Pfizer Inc. | 4-Pyrone prostaglandin antagonists |
DE3046719C2 (de) | 1980-12-11 | 1983-02-17 | Klinge Pharma GmbH, 8000 München | 1,1,2-Triphenyl-but-1-en-Derivate, Verfahren zu ihrer Herstellung und Arzneimittel |
US4418068A (en) | 1981-04-03 | 1983-11-29 | Eli Lilly And Company | Antiestrogenic and antiandrugenic benzothiophenes |
US4621100A (en) | 1981-09-25 | 1986-11-04 | The Upjohn Company | Treatment of osteoporosis with prostaglandins |
GB2126576B (en) | 1982-06-25 | 1985-06-19 | Farmos Group Limited | Alkane and alkene derivatives |
US4904478A (en) | 1983-08-11 | 1990-02-27 | Mission Pharmacal Company | Slow-release sodium fluoride tablet and method for treatment of osteoporosis |
ATE114473T1 (de) | 1984-04-30 | 1994-12-15 | Procter & Gamble | Ausrüstung für die verwendung bei der behandlung von osteoporose. |
US4729999A (en) | 1984-10-12 | 1988-03-08 | Bcm Technologies | Antiestrogen therapy for symptoms of estrogen deficiency |
EP0260066B1 (en) | 1986-09-11 | 1990-05-09 | National Research Development Corporation | Tamoxifen derivatives |
US5216183A (en) | 1988-04-19 | 1993-06-01 | Teijin Limited | Cyclopentanone/cyclopentenone derivative |
ATE150648T1 (de) * | 1990-11-26 | 1997-04-15 | Robert R Recker | Behandlung von osteoporose unter verwendung von wachstumshormon-freisetzendem faktor (grf) in verbindung mit parathyroidhormon (pth) |
JPH04312526A (ja) * | 1991-04-09 | 1992-11-04 | Fujisawa Pharmaceut Co Ltd | 骨疾患治療剤 |
US5118667A (en) * | 1991-05-03 | 1992-06-02 | Celtrix Pharmaceuticals, Inc. | Bone growth factors and inhibitors of bone resorption for promoting bone formation |
US5180720A (en) * | 1991-05-03 | 1993-01-19 | G. D. Searle & Co. | 2- and 3-alkoxy or hydroxy-8-substituted-dibenz[b,f]-[1,4]oxazepine-10(11H)-carboxylic acid, substituted hydrazides and methods for treating pain |
US5409911A (en) | 1992-09-11 | 1995-04-25 | Merck & Co., Inc. | Prostaglandin analog for treating osteoporosis |
US5578593A (en) | 1992-12-11 | 1996-11-26 | Merck & Co., Inc. | Spiro piperidines and homologs promote release of growth hormone |
SK282166B6 (sk) | 1992-12-11 | 2001-11-06 | Merck & Co., Inc. | Spiropiperidínové deriváty, spôsob ich výroby a farmaceutický prostriedok s ich obsahom |
TW383306B (en) | 1992-12-22 | 2000-03-01 | Lilly Co Eli | New use of 2-phenyl-3-aroylbenzothiophenes in lowering serum cholesterol |
TW303299B (zh) | 1993-07-22 | 1997-04-21 | Lilly Co Eli | |
KR960705575A (ko) * | 1993-10-19 | 1996-11-08 | 도나 엘. 폴락 | 비스포스포네이트와 성장 호르몬 분비촉진제와의 배합물(Combination of bishosphonates and growth hormone secretagogues) |
CN1174504A (zh) | 1993-11-09 | 1998-02-25 | 麦克公司 | 促进生长激素释放的哌啶、吡咯烷和六氢-1h-吖庚因 |
US5492916A (en) | 1993-12-23 | 1996-02-20 | Merck & Co., Inc. | Di- and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone |
CA2176140A1 (en) | 1993-11-24 | 1995-06-01 | Meng Hsin Chen | Indolyl group containing compounds and the use thereof to promote the release of growth hormone(s) |
US5441966A (en) | 1993-12-21 | 1995-08-15 | Eli Lilly And Company | Methods of inhibiting Turner's syndrome |
WO1995034311A1 (en) | 1994-06-13 | 1995-12-21 | Merck & Co., Inc. | Piperazine compounds promote release of growth hormone |
EP0779813A4 (en) * | 1994-09-09 | 1998-05-06 | Procter & Gamble | PHOSPHONATES AND PARATHORMONE AGAINST OSTEOPOROSIS |
US5552412A (en) * | 1995-01-09 | 1996-09-03 | Pfizer Inc | 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis |
US5767124A (en) | 1995-10-27 | 1998-06-16 | Merck & Co., Inc. | Polymorphic forms of a growth hormone secretagogue |
TW432073B (en) * | 1995-12-28 | 2001-05-01 | Pfizer | Pyrazolopyridine compounds |
HN1996000101A (es) * | 1996-02-28 | 1997-06-26 | Inc Pfizer | Terapia combinada para la osteoporosis |
IL120270A0 (en) * | 1996-02-28 | 1997-06-10 | Pfizer | Combination therapy to treat osteoporosis |
US6100301A (en) * | 1996-02-28 | 2000-08-08 | Pfizer Inc | Combination therapy to treat osteoporosis-polyphosphonates and estrogen agonists |
TR199802241T2 (zh) * | 1996-05-07 | 1999-02-22 | Pfizer Inc. | |
TW491847B (en) * | 1996-05-07 | 2002-06-21 | Pfizer | Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one |
CN1220609A (zh) | 1996-05-31 | 1999-06-23 | 诺沃挪第克公司 | 骨质疏松症周期性治疗中的生长激素组分和骨抗吸收剂 |
GB2324726A (en) | 1997-05-01 | 1998-11-04 | Merck & Co Inc | Combination Therapy for the Treatment of Osteoporosis |
UA53716C2 (uk) * | 1997-06-25 | 2003-02-17 | Пфайзер Продактс Інк. | Тартратна сіль заміщеного дипептиду, спосіб її одержання, проміжні сполуки та спосіб їх одержання, фармацевтична композиція (варіанти), спосіб підвищення рівнів ендогенного гормону росту та спосіб лікування або профілактики захворювань (варіанти) |
BR9803596A (pt) | 1997-09-23 | 2000-04-25 | Pfizer Prod Inc | Derivados do resorcinol. |
PA8471201A1 (es) * | 1998-06-16 | 2000-09-29 | Pfizer Prod Inc | Combinaciones terapeuticas que comprenden un modulador del receptor de estrogenos selectivo y hormona paratiroidea |
-
1996
- 1996-12-19 HN HN1996000101A patent/HN1996000101A/es unknown
- 1996-12-20 TW TW085115770A patent/TW464496B/zh not_active IP Right Cessation
- 1996-12-23 CN CNB961800585A patent/CN1242813C/zh not_active Expired - Fee Related
- 1996-12-23 CN CNA2003101202356A patent/CN1515317A/zh active Pending
- 1996-12-23 DK DK96941153T patent/DK0883404T3/da active
- 1996-12-23 PL PL35998796A patent/PL187962B1/pl not_active IP Right Cessation
- 1996-12-23 EP EP08002426A patent/EP1932543A3/en not_active Withdrawn
- 1996-12-23 CA CA2247420A patent/CA2247420C/en not_active Expired - Fee Related
- 1996-12-23 AU AU10398/97A patent/AU703285B2/en not_active Ceased
- 1996-12-23 KR KR1019980706746A patent/KR19990087337A/ko active Search and Examination
- 1996-12-23 DE DE69637651T patent/DE69637651D1/de not_active Expired - Lifetime
- 1996-12-23 UA UA98073901A patent/UA69372C2/uk unknown
- 1996-12-23 EP EP96941153A patent/EP0883404B1/en not_active Expired - Lifetime
- 1996-12-23 SK SK1183-98A patent/SK118398A3/sk unknown
- 1996-12-23 IL IL15437996A patent/IL154379A0/xx unknown
- 1996-12-23 AT AT96941153T patent/ATE405273T1/de not_active IP Right Cessation
- 1996-12-23 SI SI9630762T patent/SI0883404T1/sl unknown
- 1996-12-23 CN CNA2003101202341A patent/CN1515316A/zh active Pending
- 1996-12-23 HU HU9904123A patent/HUP9904123A3/hu unknown
- 1996-12-23 PL PL96328831A patent/PL187219B1/pl not_active IP Right Cessation
- 1996-12-23 CN CNA2003101202337A patent/CN1515254A/zh active Pending
- 1996-12-23 EP EP02010920A patent/EP1236475A3/en not_active Ceased
- 1996-12-23 US US09/117,972 patent/US6323232B1/en not_active Expired - Fee Related
- 1996-12-23 BR BR9612533A patent/BR9612533A/pt not_active Application Discontinuation
- 1996-12-23 WO PCT/IB1996/001462 patent/WO1997031640A1/en active IP Right Grant
- 1996-12-23 CZ CZ0271898A patent/CZ297452B6/cs not_active IP Right Cessation
- 1996-12-23 NZ NZ323456A patent/NZ323456A/xx unknown
- 1996-12-23 PT PT96941153T patent/PT883404E/pt unknown
- 1996-12-23 RU RU98117620/14A patent/RU2190395C2/ru not_active IP Right Cessation
- 1996-12-23 ES ES96941153T patent/ES2312169T3/es not_active Expired - Lifetime
- 1996-12-23 IL IL15438096A patent/IL154380A0/xx unknown
- 1996-12-23 JP JP9530738A patent/JPH11504352A/ja active Pending
- 1996-12-23 TR TR1998/01679T patent/TR199801679T2/xx unknown
- 1996-12-23 IL IL12549396A patent/IL125493A0/xx unknown
- 1996-12-23 CN CNA2003101202360A patent/CN1515258A/zh active Pending
-
1997
- 1997-01-16 GT GT199700009A patent/GT199700009A/es unknown
- 1997-02-13 CO CO97007548A patent/CO4761063A1/es unknown
- 1997-02-24 AR ARP970100746A patent/AR005987A1/es not_active Application Discontinuation
- 1997-02-24 PE PE2001000871A patent/PE20011302A1/es not_active Application Discontinuation
- 1997-02-24 PE PE1997000128A patent/PE58998A1/es not_active Application Discontinuation
- 1997-02-26 ID IDP970570A patent/ID19886A/id unknown
- 1997-02-26 TN TNTNSN97040A patent/TNSN97040A1/fr unknown
- 1997-02-26 DZ DZ970032A patent/DZ2186A1/fr active
- 1997-02-26 MA MA24508A patent/MA26420A1/fr unknown
- 1997-02-27 YU YU7797A patent/YU7797A/sh unknown
- 1997-02-27 UY UY2447224472A patent/UY24472A1/es not_active IP Right Cessation
- 1997-02-27 ZA ZA971719A patent/ZA971719B/xx unknown
- 1997-02-27 HR HR60/012,412A patent/HRP970118A2/xx not_active Application Discontinuation
- 1997-02-27 AP APAP/P/1997/000934A patent/AP974A/en active
- 1997-02-27 AP APAP/P/2000/001962A patent/AP975A/en active
- 1997-08-01 GT GT199700009AK patent/GT199700009AA/es unknown
-
1998
- 1998-07-28 IS IS4812A patent/IS4812A/is unknown
- 1998-08-14 OA OA9800142A patent/OA10837A/en unknown
- 1998-08-26 BG BG102726A patent/BG64582B1/bg unknown
- 1998-08-27 NO NO19983936A patent/NO323648B1/no not_active IP Right Cessation
-
1999
- 1999-07-28 HK HK99103244A patent/HK1018210A1/xx not_active IP Right Cessation
-
2000
- 2000-12-13 US US09/736,051 patent/US7255984B2/en not_active Expired - Fee Related
-
2002
- 2002-02-28 JP JP2002054756A patent/JP2002308771A/ja active Pending
- 2002-11-07 AP APAP/P/2002/002661A patent/AP1179A/en active
-
2004
- 2004-01-27 CL CL200400119A patent/CL2004000119A1/es unknown
-
2006
- 2006-08-29 NO NO20063853A patent/NO20063853L/no not_active Application Discontinuation
-
2007
- 2007-05-03 AR ARP070101915A patent/AR060853A2/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW464496B (en) | Pharmaceutical composition and kit for the treatment of bone disorders | |
EP3012250B1 (en) | Isoquinoline modulators of atp-binding cassette transporters | |
CN102292340B (zh) | 用作pde9 抑制剂的氨基-杂环类化合物 | |
RU2445095C2 (ru) | Новые фармацевтические композиции для лечения сексуальных расстройств | |
AU783165B2 (en) | Compositions and methods for treating female sexual dysfunction | |
EP1285658A2 (en) | Treatments for female sexual dysfunction | |
NL1028193C2 (nl) | Farmaceutisch werkzame verbindingen. | |
US20070054911A1 (en) | Muscarinic modulators | |
US20170107206A1 (en) | Modulators of atp-binding cassette transporters | |
HK1086267A1 (en) | Pyrimidin-2-one compounds and their use as dopamine d3 receptor ligands | |
US20080286204A1 (en) | Modulators of cftr | |
JP2019510799A5 (zh) | ||
US20060079505A1 (en) | Modulators of muscarinic receptors | |
CN103958481A (zh) | 可用于治疗的哒嗪衍生物 | |
AU2006251624A1 (en) | Modulators of ATP-Binding cassette transporters | |
JP2002503210A (ja) | ジアリールアルキル環状ジアミン誘導体およびその治療薬としての使用 | |
JPH10502658A (ja) | ドーパミン−d▲下3▼−配位子としての複素環式化合物の使用 | |
WO2005092307A3 (en) | Pharmaceutical dosage forms and compositions of 5-ht1a receptor antagonists | |
CN1370069A (zh) | 用于控制绝经热潮红的降钙素基因有关肽的拮抗剂及其释出的抑制剂 | |
CN1326456A (zh) | 8-氮杂二环[3,.2.1]辛-2-烯及-辛烷衍生物 | |
GR3020330T3 (en) | Novel bicyclic pyrimidine compounds, method for preparing same and pharmaceutical compositions containing said compounds. | |
WO1999031056A1 (fr) | Derives d'ether alcoylique ou leurs sels, et antagonistes du calcium les contenant | |
IL150222A0 (en) | Pharmaceutical compositions containing a gepirone metabolite | |
AU2012201325A1 (en) | Heterocyclic Modulators of ATP-Binding Cassette Transporters |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GD4A | Issue of patent certificate for granted invention patent | ||
MM4A | Annulment or lapse of patent due to non-payment of fees |